Viking Therapeutics, Inc. (VKTX) News
Filter VKTX News Items
VKTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VKTX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest VKTX News From Around the Web
Below are the latest news stories about VIKING THERAPEUTICS INC that investors may wish to consider to help them evaluate VKTX as an investment opportunity.
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency. |
Viking Therapeutics begins VK2735 Phase II trial for obesity treatmentScheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss. |
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss DrugThe initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days. |
3 Mid-Cap Stocks That Could Take Off in 2025Mid-cap stocks represent companies valued at between $2 billion and $10 billion. If they give investors a reason to be bullish on their growth prospects or show that they're on the right path, these types of investments can double in value and be 10-baggers in the long run. Iovance Biotherapeutics has a market cap of $2.3 billion. |
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with ObesityViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential |
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should KnowIn the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $42.53, marking a -0.84% move from the previous day. |
Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place January 13-16, 2025, in San Francisco, California. |
Why Viking Therapeutics Stock Plummeted by 24% in DecemberViking Therapeutics (NASDAQ: VKTX) didn't exactly capture investors' hearts in the final month of 2024. In mid-December, Merck announced it had entered into a licensing deal with China-based biotech Hansoh Pharma for that company's investigational weight-loss drug. If developed successfully, the drug, labeled HS-10535, would surely pose a serious threat to Viking's No. 1 pipeline program, VK2735. |
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock? |
From Davids to Goliaths: the GLP-1RA gold rushThere are more than 300 GLP-1RAs in an active stage of development, from industry giants and potential market disrupters. |